Live Analyst Rating Changes 35907 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Caitlin Roberts
CG

Caitlin Roberts

Canaccord Genuity
Wall Street Analyst
★★★☆☆
#1014
on 13Foresight · ranked by our own returns
49%
Success Rate
+2.3%
Average Return
29 of 59 calls profitable · +0.8% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 49% of Caitlin Roberts's ratings turned a profit when each position was held for 1 year — averaging +2.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

112 Buy 33 Hold 0 Sell
Caitlin's Stock Coverage 16 ratings · 2026-09-30
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
SIBN
SI-Bone
 Sep 29, 2026 BUY Strong Buy
+36.6% avg upside
18 analysts
$27.00
40.95% Upside
 · ·
SNN
Smith & Nephew Snats
 Sep 23, 2026 HOLD Buy
+23.9% avg upside
15 analysts
$30.00
11.24% Upside
 +1.0% ·
SYK
Stryker
 Sep 18, 2026 BUY Strong Buy
+29.6% avg upside
37 analysts
$385.00
38.02% Upside
 +1.3% ·
AXGN
AxoGen
 Sep 11, 2026 BUY Strong Buy
-17.2% avg upside
21 analysts
$55.00
29.66% Upside
 +2.9% ·
ENOV
Enovis
 Sep 01, 2026 BUY Strong Buy
+257.5% avg upside
39 analysts
$45.00
143.82% Upside
 -10.1% ·
OFIX
Orthofix Medical
 Aug 31, 2026 BUY Buy
+189.8% avg upside
15 analysts
$13.00
33.25% Upside
 +0.5% ·
TELA
TELA Bio
 Aug 31, 2026 BUY Strong Buy
+565.0% avg upside
9 analysts
$2.00
61.31% Upside
 +66.7% ·
GMED
Globus Medical
 Aug 28, 2026 BUY Strong Buy
+23.1% avg upside
24 analysts
$115.00
51.88% Upside
 -9.7% ·
BVS
Bioventus
 Aug 17, 2026 BUY Strong Buy
+0.4% avg upside
8 analysts
$19.00
35.79% Upside
 +1.0% ·
INMD
InMode
 Aug 17, 2026 HOLD Buy
+36.7% avg upside
9 analysts
$15.00
5.45% Upside
 -5.5% ·
KRMD
REPRO-MED Systems
 Aug 12, 2026 BUY Strong Buy
+112.0% avg upside
9 analysts
$6.00
99.59% Upside
 -2.7% ·
KIDS
OrthoPediatrics
 Aug 12, 2026 BUY Strong Buy
+40.2% avg upside
10 analysts
$28.00
23.11% Upside
 -8.5% ·
ZBH
Zimmer Biomet Holdings
 Aug 10, 2026 BUY Buy
+26.1% avg upside
38 analysts
$100.00
9.47% Upside
 -6.6% ·
ESTA
Establishment Labs Holdings
 Aug 07, 2026 BUY Strong Buy
+48.7% avg upside
12 analysts
$105.00
64.91% Upside
 -16.2% ·
VCEL
Vericel
 Jun 24, 2026 BUY Strong Buy
+14.3% avg upside
16 analysts
$58.00
42.84% Upside
 -4.8% ·
ATEC
Alphatec Holdings
 May 06, 2026 BUY Strong Buy
+61.0% avg upside
23 analysts
$23.00
121.88% Upside
 +44.8% ·
🔒 11 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Caitlin Roberts — Frequently Asked Questions
How accurate are Caitlin Roberts's stock ratings?
Based on the calls 13Foresight could measure, about 49% of Caitlin's ratings were profitable over a one-year hold, with an average return of +2.3% per rating, or +0.8% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Caitlin ranked on 13Foresight?
Caitlin Roberts is currently ranked #1014 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Caitlin cover?
Caitlin most recently has ratings on SIBN, SNN, SYK, AXGN, ENOV, OFIX, TELA, GMED, BVS, INMD, KRMD, KIDS and 4 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.